Fosun Pharma, a subsidiary of Fosun Pharmaceutical, recently received approval from the National Medical Products Administration to conduct a Phase II clinical trial of HLX22 combined with trastuzumab and chemotherapy. HLX22 is a targeted monoclonal antibody for HER2, planned for the treatment of solid tumors such as gastric cancer and breast cancer. This new drug has completed Phase I clinical research in China and is conducting Phase III clinical trials internationally. By October 2024, Fosun Pharma's research and development investment in this treatment plan is approximately 105 million yuan. According to IQVIA CHPA data, the sales of HER2-targeted monoclonal antibody products in China were about 9.5 billion yuan in 2023. Fosun Pharma plans to conduct the Phase II clinical trial of this new drug in China...Show More

Fosun Pharma, a subsidiary of Fosun Pharmaceutical, recently received approval from the National Medical Products Administration to conduct a Phase II clinical trial of HLX22 combined with trastuzumab and chemotherapy. HLX22 is a targeted monoclonal antibody for HER2, planned for the treatment of solid tumors such as gastric cancer and breast cancer. This new drug has completed Phase I clinical research in China and is conducting Phase III clinical trials internationally. By October 2024, Fosun Pharma's research and development investment in this treatment plan is approximately 105 million yuan. According to IQVIA CHPA data, the sales of HER2-targeted monoclonal antibody products in China were about 9.5 billion yuan in 2023. Fosun Pharma plans to conduct the Phase II clinical trial of this new drug in China once conditions are met. However, due to the risks inherent in new drug research and development, clinical trials may be terminated due to safety or efficacy issues. The market launch of new drugs requires a series of clinical studies and approvals, which involves uncertainty. Investors need to pay attention to related risks.